Pediatric Atopic Dermatitis: Clinical Scenarios

Overview

Release date: May 17, 2023
Expiration date: May 17, 2024
Estimated time to complete activity: 45 minutes

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.  

PROGRAM OVERVIEW

It’s estimated that 30% of the approximately 9.6 million American children with atopic dermatitis (AD) suffer from moderate to severe disease. “Suffer” is the operative word, as the disease has a wide range of deleterious effects, including unrelenting itch and sleep disturbance. When suboptimally treated, this can lead to learning disabilities and behavioral disorders resulting in long-term impact on education and psychosocial health. However, medical science is rapidly unraveling the pathogenic molecular drivers of this disease and a variety of targeted treatments have recently been approved to treat children, adolescents, and even infants with moderate to severe AD.  

Join pediatric AD experts Dr. Peter Lio and Dr. Robert Sidbury as they discuss the burden of disease of moderate to severe AD and review new and emerging therapies to treat even the youngest patients with AD. 

FACULTY

Peter A. Lio, MD    
Clinical Assistant Professor    
Dermatology and Pediatrics    
Northwestern University    
Feinberg School of Medicine    
Chicago, Illinois 

Robert Sidbury, MD, MPH   
Professor    
Department of Pediatrics   
University of Washington School of Medicine     
Division Chief, Dermatology   
Seattle Children’s Hospital    
Seattle, Washington 

TARGET AUDIENCE

This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with AD. 

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

• Describe the noncutaneous impact of moderate to severe AD on behavior, psychological health, and overall quality of life   
• Explain what is known to date about the immuno-inflammatory pathogenic drivers of pediatric AD   
• Select treatments for infants, children, and adolescents with moderate to severe AD based on findings from recent clinical trials   

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of May 17, 2023 through May 17, 2024, participants must:

• Read the learning objectives and faculty disclosures
• Complete the pretest
• Study the educational activity
• Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Peter A. Lio, MD 
Advisory Boards:AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science (KPAway), Burts Bees, Castle Biosciences, Concerto Biosciences, Dermavant, Dermira, Eli Lilly, Galderma, IntraDerm, Janssen, Johnson & Johnson, Kaleido Biosciences, Kimberly-Clark, LEO, Level Ex, Lipidor AB, L'Oréal, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, SkinFix, Theraplex, Unilever, Verrica, YobeeCare
Patent Holder: Theraplex AIM (patent pending)
Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme
Speaker:AbbVie, Eli Lilly, Galderma, Incyte, LEO, L'Oréal, Pfizer, Regeneron/Sanofi Genzyme
Stock Options: Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences, LearnSkin, Micreos, YobeeCare

Robert Sidbury, MD, MPH 
Consultant: Leo, Lilly 
Researcher: Castle, Galderma, Pfizer, Regeneron, UCB
Speaker: Beiersdorf 

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you register or participate in an educational activity sponsored by Integrity Continuing Education, Inc. (Integrity CE), you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
• Adobe® Flash® Player 10 plug-in should be downloaded
• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.